Pharmacogenetics in Primary Headache Disorders

Overview

Journal Front Pharmacol

Date 2022 Feb 28

PMID 35222013

Authors

Irina I Belyaeva

Anna G Subbotina

Ivan I Eremenko

Vadim V Tarasov

Vladimir N Chubarev

Helgi B Schioth

Jessica Mwinyi

Affiliations

Soon will be listed here.

Abstract

Primary headache disorders, such as migraine, tension-type headache (TTH), and cluster headache, belong to the most common neurological disorders affecting a high percentage of people worldwide. Headache induces a high burden for the affected individuals on the personal level, with a strong impact on life quality, daily life management, and causes immense costs for the healthcare systems. Although a relatively broad spectrum of different pharmacological classes for the treatment of headache disorders are available, treatment effectiveness is often limited by high variances in therapy responses. Genetic variants can influence the individual treatment success by influencing pharmacokinetics or pharmacodynamics of the therapeutic as investigated in the research field of pharmacogenetics. This review summarizes the current knowledge on important primary headache disorders, including migraine, TTH, and cluster headache. We also summarize current acute and preventive treatment options for the three headache disorders based on drug classes and compounds taking important therapy guidelines into consideration. Importantly, the work summarizes and discusses the role of genetic polymorphisms regarding their impact on metabolism safety and the effect of therapeutics that are used to treat migraine, cluster headache, and TTH exploring drug classes such as nonsteroidal anti-inflammatory drugs, triptans, antidepressants, anticonvulsants, calcium channel blockers, drugs with effect on the renin-angiotensin system, and novel headache therapeutics such as ditans, anti-calcitonin-gene-related peptide antibodies, and gepants. Genetic variants in important phase I-, II-, and III-associated genes such as cytochrome P450 genes, UGT genes, and different transporter genes are scrutinized as well as variants in genes important for pharmacodynamics and several functions outside the pharmacokinetic and pharmacodynamic spectrum. Finally, the article evaluates the potential and limitations of pharmacogenetic approaches for individual therapy adjustments in headache disorders.

Citing Articles

The Power of and Gene Expression and Methylation Status in the Diagnosis-Treatment-Cause Triangle in Tension-Type Headache.

Kilicaslan F, Geyik S, Yilmaz S Curr Issues Mol Biol. 2024; 46(11):12756-12768.

PMID: 39590352 PMC: 11592980. DOI: 10.3390/cimb46110758.

Managing Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities.

Burish M, Guirguis A, Schindler E Curr Neurol Neurosci Rep. 2024; 24(9):439-452.

PMID: 39017830 DOI: 10.1007/s11910-024-01362-x.

Primary Dengue and Long-Term Health Status in Madeira Island, Portugal: A Retrospective Questionnaire-Based Study.

Henriques P, Caldeira-Araujo H, Brazao M, Abreu A, Vigario A, Rosa A Am J Trop Med Hyg. 2024; 111(2):403-411.

PMID: 38955194 PMC: 11310610. DOI: 10.4269/ajtmh.23-0502.

New management strategies for primary headache disorders: Insights from P4 medicine.

Zhang Y, Huang W, Pan S, Shan Z, Zhou Y, Gan Q Heliyon. 2023; 9(11):e22285.

PMID: 38053857 PMC: 10694333. DOI: 10.1016/j.heliyon.2023.e22285.

Genetics of migraine: where are we now?.

Grangeon L, Lange K, Waliszewska-Prosol M, Onan D, Marschollek K, Wiels W J Headache Pain. 2023; 24(1):12.

PMID: 36800925 PMC: 9940421. DOI: 10.1186/s10194-023-01547-8.

References

Diener H, Bussone G, van Oene J, Lahaye M, Schwalen S, Goadsby P . Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27(7):814-23. DOI: 10.1111/j.1468-2982.2007.01326.x. View

Erdemoglu A, Varlibas A . The long-term efficacy and safety of botulinum toxin in refractory chronic tension-type headache. J Headache Pain. 2007; 8(5):294-300. PMC: 3476152. DOI: 10.1007/s10194-007-0414-7. View

Ho T, Ferrari M, Dodick D, Galet V, Kost J, Fan X . Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372(9656):2115-23. DOI: 10.1016/S0140-6736(08)61626-8. View

. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

Burch R, Buse D, Lipton R . Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019; 37(4):631-649. DOI: 10.1016/j.ncl.2019.06.001. View

Zobdeh F, Ben Kraiem A, Attwood M, Chubarev V, Tarasov V, Schioth H . Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol. 2021; 178(23):4588-4607. DOI: 10.1111/bph.15657. View

Ahn A, Basbaum A . Where do triptans act in the treatment of migraine?. Pain. 2005; 115(1-2):1-4. PMC: 1850935. DOI: 10.1016/j.pain.2005.03.008. View

Kamide K, Yang J, Matayoshi T, Takiuchi S, Horio T, Yoshii M . Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers. Circ J. 2009; 73(4):732-40. DOI: 10.1253/circj.cj-08-0761. View

Diener H, Dodick D, Aurora S, Turkel C, DeGryse R, Lipton R . OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30(7):804-14. DOI: 10.1177/0333102410364677. View

10.

Gildir S, Tuzun E, Eroglu G, Eker L . A randomized trial of trigger point dry needling versus sham needling for chronic tension-type headache. Medicine (Baltimore). 2019; 98(8):e14520. PMC: 6408118. DOI: 10.1097/MD.0000000000014520. View

11.

FROHNER R . Cortisone in migraine and histamine headaches. Rocky Mt Med J. 1953; 50(11):882. View

12.

Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P . Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain. 2010; 11(5):431-5. PMC: 3452274. DOI: 10.1007/s10194-010-0241-0. View

13.

Sim S, Risinger C, Dahl M, Aklillu E, Christensen M, Bertilsson L . A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79(1):103-13. DOI: 10.1016/j.clpt.2005.10.002. View

14.

Gonen M, Balgetir F, Aytac E, Tasci I, Demir C, Mungen B . Suboccipital steroid injection alone as a preventive treatment for cluster headache. J Clin Neurosci. 2019; 68:140-145. DOI: 10.1016/j.jocn.2019.07.009. View

15.

Halker R, Starling A, Vargas B, Schwedt T . ACE and ARB Agents in the Prophylactic Therapy of Migraine-How Effective Are They?. Curr Treat Options Neurol. 2016; 18(4):15. DOI: 10.1007/s11940-016-0397-2. View

16.

Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, DAlessandro R . Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2014; 35(2):118-31. DOI: 10.1177/0333102414550416. View

17.

Gormley P, Anttila V, Winsvold B, Palta P, Esko T, Pers T . Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016; 48(8):856-66. PMC: 5331903. DOI: 10.1038/ng.3598. View

18.

Wei D, Khalil M, Goadsby P . Managing cluster headache. Pract Neurol. 2019; 19(6):521-528. PMC: 6902063. DOI: 10.1136/practneurol-2018-002124. View

19.

Fang J, Yuan X, An X, Qu H, Wang C, Hong G . Involvement of the Tetraspanin 2 () Gene in Migraine: A Case-Control Study in Han Chinese. Front Neurol. 2018; 9:714. PMC: 6143784. DOI: 10.3389/fneur.2018.00714. View

20.

Daly A, Aithal G, Leathart J, Swainsbury R, Dang T, Day C . Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007; 132(1):272-81. DOI: 10.1053/j.gastro.2006.11.023. View